Brevity is Paramount

 

The first patient’s cells in the Novartis Morris Plains processing facility have arrived as part of the global clinical trial of CTL019, an investigational chimeric antigen receptor (CAR) T cell therapy. CTL019 is being investigated in certain life-threatening B-cell cancers such as B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), and chronic lymphoblastic leukemia (CLL). 

 

In the video above, Novartis employees from the Cell and Gene Therapies Unit share the enthusiasm and pride they feel about reaching this important milestone and their passion for the patients they serve.